Browsing by Author "Ziegler-Rodriguez, G"

Now showing 1 - 5 of 5

ASO Author Reflections: Distilling Wisdom From Two Decades of Cutaneous Malignant Melanoma at a Peruvian Cancer Institute: A Stirring Call for Action
(Springer Science and Business Media Deutschland GmbH, 2024) Ziegler-Rodriguez, G; Ziegler-Rodriguez, O; De, La, Cruz-Ku, G; Cotrina-Concha, JM; Dunstan, J; Pinillos-Portella, M; Vilchez-Santillan, S; Möller, MG
Resumen disponible en la revista donde esta publicada
Correction to: Unveiling Melanoma: A Deep Dive into Disparities at a Latin-American Cancer Institute (Annals of Surgical Oncology, (2024), 31, 9, (6097-6117), 10.1245/s10434-024-15573-6)
(Springer Science and Business Media Deutschland GmbH, 2024) Ziegler-Rodriguez, G; De, La, Cruz-Ku, G; Piedra-Delgado, L; Torres-Maldonado, J; Dunstan, J; Cotrina-Concha, JM; Galarreta-Zegarra, JA; Calderon-Valencia, G; Vilchez-Santillan, S; Pinillos-Portella, M; Möller, MG
In the original online version of this article Luis Piedra‑Delgado's affiliation was incorrect. It is correct as reflected here. The original article was corrected.
Descripción de un caso de adenomatosis erosiva del pezón: tratamiento quirúrgico
(Spanish Society of Senology and Breast Pathology, 2023) Chavez-Diaz, M; Ziegler-Rodriguez, G; Montes-Gil, J
Erosive adenomatosis is a rare benign neoplasm that affects the nipple. Characterized by erosion, telorrhoea, telorrhagia, nodularity, pruritus and erythema, causing a progressive destructive process of the nipple, which can be confused with Paget's disease; which is why knowledge of this pathology is essential to avoid surgical overtreatment. We present the case of a 35-year-old patient diagnosed and treated with surgery, as well as a review of the literature on this entity. © 2023
Prepectoral and Retropectoral Breast-implant-Associated Anaplastic Large-cell Lymphoma
(Lippincott Williams and Wilkins, 2024) Ziegler-Rodriguez, G; Garces-Ruiz, M; De, La, Cruz-Ku, G; Ziegler-Rodriguez, O; Ziegler-Gutierrez, O; Garces-Castre, M; Montes-Gil, J; Neira, J; Taxa-Rojas, L; Cebrian, R; Chatterjee, A
Summary: Breast-implant-associated anaplastic large cell lymphoma (BIA-ALCL) is a non-Hodgkin lymphoma that arises in the space between the surface of a breast implant and the fibrous capsule that grows around the implant. Since its first description 20 years ago, almost 1000 cases of BIA-ALCL have been diagnosed worldwide. Nowadays, guidelines describe the diagnosis, staging, and treatment of this disease. We present the first two cases diagnosed and treated in Peru, demonstrating a wide range of aggressiveness of BIA-ALCL. © Plastic and Reconstructive Surgery - Global Open.All rights reserved.
Unveiling Melanoma: A Deep Dive into Disparities at a Latin-American Cancer Institute
(Springer Science and Business Media Deutschland GmbH, 2024) Ziegler-Rodriguez, G; De, La, Cruz-Ku, G; Piedra-Delgado, L; Torres-Maldonado, J; Dunstan, J; Cotrina-Concha, JM; Galarreta-Zegarra, JA; Calderon-Valencia, G; Vilchez-Santillan, S; Pinillos-Portella, M; Möller, MG
Introduction: The worldwide incidence of melanoma has increased in the last 40 years. Our aim was to describe the clinic-pathological characteristics and outcomes of three cohorts of patients diagnosed with melanoma in a Latin-American cancer institute during the last 20 years. Methods: We evaluated three retrospective patient cohorts diagnosed with melanoma at Instituto Nacional de Enfermedades Neoplasicas (INEN), a public hospital in Lima, Peru, for the years 2005–2006, 2010–2011, and 2017–2018. Survival rate differences were assessed using the Log-rank test. Results: Overall, 584 patients were included (only trunk and extremities); 51% were male, the mean age was 61 (3–97) years, and 48% of patients resided in rural areas. The mean time to diagnosis was 22.6 months, and the mean Breslow thickness was 7.4 mm (T4). Lower extremity was the most common location (72%). A majority of the patients (55%) had metastases at the time of presentation, with 36% in stage III and 19% in stage IV. Cohorts were distributed as 2005–2006 (n = 171), 2010–2011 (n = 223), and 2017–2018 (n = 190). No immunotherapy was used. Cohort C exhibited the most significant increase in stage IV diagnoses (12.3%, 15.7%, 28.4%, respectively; p < 0.01). The median overall survival rates at the three-year follow-up demonstrated a decline over the years for stages II (97%, 98%, 57%, respectively; p < 0.05) and III (66%, 77%, 37%; p < 0.01). Conclusions: There has been a worsening in the incidence of late-stage metastatic melanoma in Peru throughout the years, coupled with a significant decline in overall survival rates. This is underscored by the fact that half of the population lives in regions devoid of oncological access.